Overview

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Lurasidone Hydrochloride